Suppr超能文献

合并症对住院 COVID-19 叙利亚患者的影响:一项回顾性研究。

Impact of comorbidities on hospitalised Syrian patients with COVID-19: a retrospective study.

机构信息

Faculty of Medicine, Syrian Private University, Damascus, Syrian Arab Republic.

Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic.

出版信息

BMJ Open. 2023 Mar 20;13(3):e068849. doi: 10.1136/bmjopen-2022-068849.

Abstract

OBJECTIVES

This study aims to compare the clinical manifestations, laboratory findings, outcomes and overall survival time of patients with COVID-19 with and without comorbidities.

DESIGN

Retrospective design.

SETTING

This study was undertaken at two hospitals in Damascus.

PARTICIPANTS

A total of 515 Syrian patients met the inclusion criterion, laboratory-confirmed COVID-19 infection following the Centers for Disease Control and Prevention. Exclusion criteria were suspected and probable cases that were not confirmed with a positive reverse transcription-PCR assay, and patients who self-discharged from the hospital against medical advice.

PRIMARY AND SECONDARY OUTCOME MEASURES

First, assess the impacts of comorbidities on COVID-19 infection in four areas (clinical manifestations, laboratory findings, severity and outcomes). Second, calculate the overall survival time for patients with COVID-19 with comorbidities.

RESULTS

Of 515 patients included, 316 (61.4%) were male and 347 (67.4%) had at least one coexisting chronic disease. Patients with comorbidities compared with no comorbidities were more vulnerable to poor outcomes such as severe infection (32.0% vs 9.5%, p<0.001), severe complications (34.6% vs 9.5%, p<0.001), the need for mechanical ventilation (28.8% vs 7.7%, p<0.001) and death (32.0% vs 8.3%, p<0.001). Multiple logistic regression showed that age ≥65 years old, positive smoking history, having ≥2 comorbidities and chronic obstructive pulmonary disease were risk factors linked to severe COVID-19 infection in patients with comorbidities. Overall survival time was lower among patients with comorbidities (vs no comorbidities), patients with ≥2 comorbidities (vs one comorbidity), and patients with hypertension, chronic obstructive pulmonary disease, malignancy or obesity (vs other comorbidities) (p<0.05).

CONCLUSION

This study revealed that COVID-19 infection had poor outcomes among those with comorbidities. Severe complications, mechanical ventilation usage and death were more prevalent among patients with comorbidities compared with those with no comorbidities.

摘要

目的

本研究旨在比较合并症和无合并症 COVID-19 患者的临床表现、实验室检查结果、结局和总生存时间。

设计

回顾性设计。

地点

本研究在大马士革的两家医院进行。

参与者

共有 515 名叙利亚患者符合纳入标准,即经美国疾病控制与预防中心实验室确诊的 COVID-19 感染。排除标准为疑似和可能病例,未通过阳性逆转录-聚合酶链反应检测证实,以及未经医嘱擅自出院的患者。

主要和次要结局测量

首先,评估合并症对 COVID-19 感染在四个方面(临床表现、实验室检查结果、严重程度和结局)的影响。其次,计算合并症 COVID-19 患者的总生存时间。

结果

在 515 例患者中,316 例(61.4%)为男性,347 例(67.4%)至少合并一种慢性疾病。与无合并症患者相比,合并症患者更容易出现不良结局,如严重感染(32.0%比 9.5%,p<0.001)、严重并发症(34.6%比 9.5%,p<0.001)、需要机械通气(28.8%比 7.7%,p<0.001)和死亡(32.0%比 8.3%,p<0.001)。多因素逻辑回归显示,年龄≥65 岁、阳性吸烟史、合并≥2 种疾病和慢性阻塞性肺疾病是合并症患者发生严重 COVID-19 感染的危险因素。与无合并症患者相比,合并症患者(与无合并症患者相比)、合并≥2 种疾病患者(与合并 1 种疾病患者相比)、合并高血压、慢性阻塞性肺疾病、恶性肿瘤或肥胖患者(与其他合并症患者相比)的总生存时间较低(p<0.05)。

结论

本研究表明,合并症患者的 COVID-19 感染结局较差。与无合并症患者相比,合并症患者更常见严重并发症、需要机械通气和死亡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9272/10030286/4bcd1122955b/bmjopen-2022-068849f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验